Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-25T16:38:44.573Z Has data issue: false hasContentIssue false

Tardive dyskinesia – how is it prevented and treated?

Published online by Cambridge University Press:  02 January 2018

James G. Longhurst
Affiliation:
Department of Psychiatry and Connecticut Mental Health Center, School of Medicine, Yale University, 34 Park Street, New Haven, Connecticut 06519
Erica L. Weiss
Affiliation:
Department of Psychiatry and Connecticut Mental Health Center, School of Medicine, Yale University, 34 Park Street, New Haven, Connecticut 06519
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1997 The Royal College of Psychiatrists

References

Casey, D. E. (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesa. Psychopharmacology, 99, S47S53.CrossRefGoogle Scholar
Tamminga, C. A., Thaker, G. K., Moran, M., et al (1994) Clozapine in tardive dyskinesia: observations from human and animal model studies. Journal of Clinical Psychiatry, 55 (suppl B), 102106.Google ScholarPubMed
Young, C. R., Longhurst, J. G., Bowers, M. B., et al (1997) The expanding indications for clozapine. Journal of Clinical and Experimental Psychopharmacology, 5, 120.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.